As hep C rev­enue dis­in­te­grates, pres­sure keeps grow­ing on Gilead to do deals

Gilead’s hep C busi­ness is get­ting shred­ded by grow­ing com­pe­ti­tion and dis­count prices. Next year the com­pa­ny ex­pects to see its $14.8 bil­lion in 2016 hep C rev­enue melt down to $7.5 bil­lion to $9 bil­lion. And the rapid dis­in­te­gra­tion is build­ing pres­sure on the big biotech to fi­nal­ly get down to busi­ness and use its con­sid­er­able fi­nan­cial re­serves for some M&A and ma­jor deal­mak­ing.

Of course, that’s been said be­fore. An­a­lysts have been urg­ing Gilead to get am­bi­tious on the busi­ness de­vel­op­ment side of things for the past two years. 2017, though, may prove to be a year that Gilead’s path to whip­ping up some ex­cite­ment for its fu­ture lies al­most sole­ly in new ac­qui­si­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER